StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the stock.
Oragenics Price Performance
NYSE:OGEN opened at $1.07 on Thursday. Oragenics has a one year low of $1.00 and a one year high of $7.74. The stock has a 50-day moving average price of $1.48.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings results on Friday, March 29th. The company reported ($5.48) earnings per share for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Recommended Stories
- Five stocks we like better than Oragenics
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 4/29 – 5/3
- How to Use Stock Screeners to Find Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to Invest in Blue Chip Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
